Department of Error (DOI:10.1016/S0140-6736(09)60598-5);Migraine and olcegepant

The Lancet

Volumn 373, Issue 9668, 2009, Pages 1003-

  Tfelt Hansen, Peer ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMIGRAINE AGENT; OLCEGEPANT; PLACEBO; TELCAGEPANT; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

ANALGESIA; CLINICAL TRIAL; DRUG EFFICACY; HEADACHE; HUMAN; LETTER; MIGRAINE; PAIN ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 62349116085     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60687-5     Document Type: Erratum

References (4)

1. Ho T.W., Ferrari M.D., Dodick D.W., et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 372 (2008) 2115-2123
2. International Headache Society Clinical Trial Subcommittee. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 20 (2000) 765-786
3. Santanello N.C., Hartmaier S.L., Epstein R.S., and Silberstein S.D. Validation of a new quality of life questionnaire for acute migraine headache. Headache 35 (1995) 330-337
4. Tfelt-Hansen P. Early responses in randomised clinical trials of triptans in acute migraine treatment: are they clinically relevant?. Headache (2008) 10.1111/j.1526-4610.2008.01285.x published online Oct 10.